Correlation between blood levels of cadmium and lead and the expression of microRNA-21 in Egyptian bladder cancer patients

Amira Awadalla a, Wael I. Mortadab, Hassan Abol-Eneina, Ahmed A. Shokeira, a

a Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt
b Clinical Chemistry Laboratory, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt

ARTICLE INFO

Keywords:
Environmental pollution
Gene expression
Cancer research
Oncology
Toxicology
Clinical research
Cadmium
Lead
miRNA-21
Bladder cancer

ABSTRACT

Objective: To investigate the relationship between blood levels of cadmium (Cd) and lead (Pb) and the expression of miRNA-21 among bladder cancer (BC) patients.

Material and methods: The blood concentrations of Cd and Pb in 268 BC patients and 132 controls were determined by inductively coupled plasma optical emission spectrometry (ICP-OES). The blood concentrations of Cd and Pb were interpreted according to the type and stage of the carcinoma. The expression of miRNA-21 was assessed by quantitative reverse transcription polymerase chain reaction in cancerous and adjacent non-cancerous bladder tissues among the patient groups.

Results: The blood concentrations of Cd and Pb were statistically elevated in BC patients compared to those of the controls. This elevation is more prevalent in groups with muscle-invasive bladder cancer (MIBC) than those with non-muscle invasive bladder cancer (NMIBC). Among the BC group, miRNA-21 was upregulated in cancerous tissues relative to adjacent non-cancerous tissues. Moreover, the expression was significantly higher in patients with MIBC compared to those with NMIBC. The expression of miRNA-21 in cancerous tissues was significantly associated with blood concentration of Cd and Pb among BC patients.

Conclusion: There is a relationship between Cd and Pb body burden and the tissue expression of miRNA-21 among BC patients. This indicates the role of miRNA-21 in Cd and Pb induced BC.

1. Introduction

Cadmium (Cd) and lead (Pb) are biohazard heavy metals that threaten human health. Although they are distributed naturally, their concentrations are increased in the environment due smelting, batteries manufacture, ceramics and pigments industries (Andjelkovic et al., 2019). Cd and Pb are present in air, food and water, and their toxic effects depend upon the route and the dose of exposure (Tchounwou et al., 2012). The World Health Organization (WHO) has reported that Cd and Pb are two of the most toxic chemicals to human health (WHO 2010). Cd and Pb are in the seventh and second orders on the priority list of serious matters (ATSDR 2019). Both metals exert toxic effects on liver, kidneys, cardiovascular, reproductive and hematopoietic systems by different mechanisms (Andjelkovic et al., 2019). Oxidative stress and binding to body proteins and enzymes are the most important mechanisms of Cd and Pb toxicity (Matović et al., 2015; Vujotić et al., 2020). Heavy metals, including Cd and Pb, may also cause damage of DNA (Flora et al., 2012).

Bladder cancer is a common neoplasm of the urinary system. Some environmental factors including heavy metals participate in the etiology of BC (Chang et al., 2016). Epidemiological studies showed possible associations between Cd or Pb and BC (Feki-Tounsi et al. 2013, 2014; Golabek et al., 2009). United States Environmental Protection Agency (US-EPA) has defined Cd as possible human carcinogen (Huff et al., 2007). The mechanism of Cd carcinogenesis is complex however gene expression deregulation plays a critical part in this matter (Feki-Tounsi and Hamza-Ghaffai 2014). Elevated levels of Pb were detected in blood and cancerous tissues of BC patients, suggesting its contribution to development of BC (Golabek et al., 2009).

MicroRNAs (miRNAs) are short non-coding RNA sequences. It can control gene expression and regulate vital cellular pathways. They are involved in initiation and development of cancers (Hou et al., 2011). Evidences demonstrates that exposure toxic metals affect miRNA expression (Wallace et al., 2020). miRNA-21 has been reported to be one of the most commonly up-regulated miRNAs in various human cancers functioning as a key regulator of carcinogenic process, and has been...
considered as a novel target in cancer monitoring (Bautista-Sánchez et al., 2020). It is interesting that recent studies also show that miRNA-21 is critically involved in heavy metals-induced cell malignant transformation and tumorigenesis (Wallace et al., 2020). Alteration of miRNA expression is associated with Cd carcinogenesis in prostatic cancer (Moustafa et al., 2018), pancreatic cancer (Wallace et al., 2019), thyroid cancer (Buha et al., 2018) and ovarian cancer (Wang et al., 2018). Association between Pb toxicity and changes in expression of different types of miRNA has also been observed in many diseases such as neurotoxicity (Masoud et al., 2016), nephropathy (Siddeek et al., 2014) and cancers (Feng and Tsao 2016). Few studies were conducted to investigate changes in the expression of miRNAs in response to Cd and Pb exposure (Lei et al., 2019). It would be very interesting to determine whether miRNA-21 is involved in the correlation between BC progression and Cd and Pb exposure.

To the best of our knowledge, the present study is the first to explore the relation between Cd and Pb concentrations in blood and expression of miRNA-21 in cancerous tissues among BC patients. The study aims to add additional information about BC pathogenesis that may be helpful for reducing incidence and recurrence of the disease.

2. Materials and methods

2.1. Study population

The pre-operative study was conducted at the Urology and Nephrology Center, Mansoura University that serve Dakahlia Governorate in Egypt during 3 years period from 2015-2018. The A total of 268 patients with different stages of BC were included in the study. The patients recruited for the study were first diagnosed with BC. The diagnosis of BC was confirmed by cystoscopy, biopsy and histopathological examinations. Patients were grouped according to their histopathological reports as transitional cell carcinoma (TCC, n = 148) or squamous cell carcinoma (SCC, n = 120). Each group was subdivided into two subgroups, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) based on the stage of cancer. Exclusion criteria were the presence of known occupational exposure to heavy metals, chemotherapy, radiotherapy and other malignant diseases. The study included a control group of 132 matched individuals with neither tumor nor heavy metal exposure history. Informed consent was obtained from each person. All participants had normal kidney functions (estimated by plasma creatinine analysis) and normal hepatic functions (determined by analysis of plasma transaminases and bilirubin). The study was approved by our local Institutional Review Board (IRB) (IRB #RP-17.12.301). The characteristics of all groups were summarized in Table 1.

2.2. Analysis of Cd and Pb

Venous blood samples for analysis of Cd and Pb were collected from all individuals in metal free tubes (Royal blue vacutainer tubes) containing K₂EDTA and were preserved at -20 °C. Samples were digested within a month of collection as previously prescribed (Mortada et al., 2017). Briefly, 1 mL of blood sample was mixed with 4 mL of HNO₃ and 2 mL of H₂O₂ in Teflon digested tube and then kept for 20 min at room temperature. The closed tubes were processed in the microwave digestion system (Speed wave four, Berghof Products, Germany) according to the following program: power, 1600 W (100%); ramp time, 15 min; temperature, 200 °C; hold time, 15 min; and cooling time, 15 min. After cooling, the solution was diluted to 10 mL by distilled water and filtered (if necessary), then subjected for analysis of Cd and Pb by inductively coupled plasma optical emission spectrometry (Agilent technologies 700 ICP-OES Series, Santa Clara, CA, USA). The instrumental parameters were adjusted according to the manufacturer specifications (Table 2). Accuracy was tested at the start of each run by analysis of certified reference material (Seronorm™ Trace Elements Whole Blood L-2, Sero, Norway).

2.3. miRNA-21 quantification by real-time (RT)-qPCR

Two tissue samples were obtained from each BC patient: the first was collected from central part of the tumor and the second which served as a control was taken from non-lesion part of the tissue. Tissue samples for miRNA analysis were preserved in RNA later at -80 °C. Total RNA including miRNAs was extracted from bladder tissues using mirNeasy Mini Kit (cat.# 217004, Qiagen, Hilden, Germany), then it reverse transcribed to cDNA in a final volume of 20 μL using the miScript Reverse Transcription kit (cat.# 218161, Qiagen, Hilden, Germany). The qPCR measurements were done in triplicate using miScript SYBR-Green PCR kit (SYBR® Green PCR Kit) (cat.# 218073, Qiagen, Hilden, Germany) and miScript primer assay for miRNA-21 on the Rotor-Gene Q 5-Plex (Qiagen) according to the manufacturer’s instructions. The results were normalized to SNORD68_11 (sn68) (Qiagen). The amplification profile was denatured at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min and 70 for 30 °C s. The expression level of miRNA

---

**Table 1. Characteristics of the study groups.**

|                      | Control group | SCC group | TCC group | p value* |
|----------------------|---------------|-----------|-----------|----------|
| **Number of subjects** | 132           | 120       | 148       |          |
| NMIBC-MIBC           | -             | 21:99     | 31:117    |          |
| **Categorical variables, n (%)** |               |           |           |          |
| **Gender**           |               |           |           |          |
| Male                 | 100 (75.7)    | 91 (75.8) | 115 (77.7)| 0.44     |
| Female               | 32 (24.3)     | 29 (24.2) | 33 (22.3) | 0.51     |
| Smokers              | 34 (25.7)     | 34 (28.3) | 40 (27.0) | 0.32     |
| Hypertension         | 29 (22.0)     | 30 (25.0) | 36 (24.3) | 0.18     |
| Diabetes             | 23 (17.4)     | 21 (17.5) | 28 (18.9) | 0.28     |

**Continuous variables, Mean ± SD**

|               | Control group | SCC group | TCC group | p value* |
|---------------|---------------|-----------|-----------|----------|
| Age (year)    | 54.0 ± 7.7    | 61.4 ± 6.4| 58.5 ± 8.9| 0.46     |
| BMI (kg/m²)   | 25.9 ± 4.0    | 27.4 ± 3.7| 26.1 ± 4.9| 0.52     |
| Serum creatinine (mg dL⁻¹) | 0.81 ± 0.07 | 0.89 ± 0.06 | 0.84 ± 0.08 | 0.71 |
| ALT (IU L⁻¹)  | 26.8 ± 4.1    | 31.7 ± 4.9| 29.4 ± 5.8| 0.44     |
| AST (IU L⁻¹)  | 16.5 ± 3.9    | 18.4 ± 3.7| 21.9 ± 4.3| 0.36     |
| Bilirubin (mg dL⁻¹) | 0.7 ± 0.1 | 0.6 ± 0.2 | 0.7 ± 0.2 | 0.66     |

* One way ANOVA for continuous variables and Chi-square test for categorical variables.
gene was represented by fold change, which was calculated using the equation $2^{-\Delta\Delta CT}$ (Livak and Schmittgen 2001).

2.4. Statistical analyses

Statistical computations were performed by SPSS-PC software (MAS Medical & Scientific Eq. Co, IL, USA). Kolmogorov-Smirnov test indicated normal distribution of all variables. Accordingly, continuous data were expressed as mean ± standard deviation (SD) while categorical variables were presented as number and percentage. Comparisons between groups were made using ANOVA and Chi-square test as appropriate. The partial correlation coefficient ($r$) was estimated to determine the relation between blood levels of Cd and Pb with cancerous tissue expression of miRNA21, after controlling for age and BMI. $p$-value ≤ 0.05 was defined as significant.

3. Results

Table 1 displays the descriptive features of study groups. The mean age of the study groups were comparable. Most of BC cases were MIBC ($n = 99, 85.5\%$ for SCC; $n = 117, 79.1\%$ for TCC). No significant differences were observed between the groups concerning gender, BMI, smoking habit, clinical and biochemical data.

| Metal ion | Power (kW) | Plasma gas flow (L min$^{-1}$) | Auxiliary gas flow (L min$^{-1}$) | Nebulizer gas flow rate (L min$^{-1}$) | Delay time (sec) | Wavelength (nm) | Detection limit (μgL$^{-1}$) |
|-----------|------------|-------------------------------|-----------------------------------|---------------------------------------|-----------------|----------------|-------------------|
| Cd        | 1.4        | 15                            | 1.5                               | 0.7                                   | 12              | 226.502        | 0.2               |
| Pb        |            |                               |                                   |                                       | 220.353         | 1.8            |                   |

Table 2. ICP-OES instrument parameters for determination of Cd and Pb.

Figure 1. (a) Cd and (b) Pb levels in NMIBC and MIBC of TCC and SCC groups versus controls (NMI-TCC = non-muscle invasive transition cell carcinoma, MI-TCC = muscle invasive transition cell carcinoma, NMI-SCC = non-muscle invasive squamous cell carcinoma, MI-SCC = muscle invasive squamous cell carcinoma).

Figure 2. The expression of miRNA-21 in cancerous and adjacent non-cancerous tissues in (a) TCC group and (b) SCC group (NMI-TCC = non-muscle invasive transition cell carcinoma, MI-TCC = muscle invasive transition cell carcinoma, NMI-SCC = non-muscle invasive squamous cell carcinoma, MI-SCC = muscle invasive squamous cell carcinoma).
Figure 1 presents the levels of blood Cd and Pb from cancer and control groups. Significantly elevated concentrations of blood Cd and Pb were detected in TCC and SCC groups when compared to the controls ($p < 0.001$). It is also evident that Cd and Pb levels in blood among both TCC and SCC groups were significantly higher in MIBC patients than those with NMIBC ($p < 0.01$ in case of Cd and $p < 0.05$ regarding Pb). The elevated levels in the study groups didn’t reach the level of toxicity stated by the international communities. In adults, Pb blood levels up to 100 μg L$^{-1}$ are considered normal (CDC 2013), while the normal blood Cd concentration is less than 5 μg L$^{-1}$ (Moyer 2015). The elevated levels in our patients didn’t reach these levels.

The results in Figure 2 display comparison between expression of miRNA21 in cancerous bladder tissues and adjacent non-cancerous bladder tissues in SCC and TCC groups. The expressions of miRNA21 in bladder cancerous tissues in both SCC and TCC groups were significantly higher ($p < 0.001$) when compared to those in the adjacent non-cancerous tissues. Moreover, miRNA21 was upregulated in MIBC patients when compared to those of NMIBC patients within the same group ($p < 0.001$ in TCC group and $p < 0.01$ in SCC).

Table 3 presents the partial correlation coefficient values ($r$) between levels of blood Cd or Pb with expression of miRNA21 in cancerous bladder tissue among TCC and SCC groups. As shown, expression of miRNA21 in cancerous tissue is positively correlated with blood levels of Cd or Pb ($p < 0.001$ except between blood Cd and miRNA21 in SCC group).

4. Discussion

The recurrence of BC continues to impede its treatment. Multiple factors are involved in the pathogenesis of BC, however genetics and environmental factors are the most contributed sources (Volanis et al., 2010). Heavy metals such as Cd and Pb increase the risk of urothelial carcinogenesis (Chang et al., 2016). The exact mechanism of carcinogenesis of Cd and Pb is still undefined. Alteration in oxidative stress (Abdeen et al., 2019) and failure in DNA repair may cause genetic mutation accompanied by abnormal gene expression that involve in the cancer prognosis (Al Bakheet et al., 2013). Exposure to Cd$^{2+}$ led to a cancerous transformation in human urothelial cell lines (Sens et al., 2004). Both Cd and Pb also induced genes linked to cell signaling and metabolism (Koedrith et al., 2013; Koizumi and Yamada 2003). Generally, heavy metals initiate or promote cancer by different cellular mechanisms including cellular redox imbalance and changes in genetic and epigenetic factors (Koedrith et al., 2013). The role of miRNA in carcinogenic effects of heavy metals is still unclear due to limited studies (Humphries et al., 2016). Therefore, our study is aimed to study the correlation between Cd and Pb levels in blood and expression of miRNA21 in patients with different stages of TCC and SCC.

Blood Cd and Pb are considered good indicators of body burden as they are strongly correlated with urinary and tissue levels (JÅker and Åkesson 2009; Mendy et al., 2012). In the present work, BC patients (TCC and SCC) exhibited higher levels of Cd and Pb compared to controls. These findings agree with other previous studies. Many investigators have observed a relationship between Cd and Pb exposure to elevated risk of BC. Golabek et al., (2009) reported higher blood levels of Pb in BC patients compared to controls. In a Belgian case-control study, exposure to Cd elevated the risk of BC development (Kellen et al., 2007). The statistically significant elevation of Cd and Pb blood levels among MIBC patients compared to those with NMIBC suggest a correlation between exposure to Cd and Pb and the progression of BC.

miRNAs are short non-coding RNAs that have a significant function in controlling differentiation, proliferation, apoptosis and autophagy (Liu et al., 2017). Dysregulation of miRNAs was observed in different types of cancer and their expressions were associated with pathogenesis and features of the disease (Ambros 2004). In our study, high expression of miRNA21 was observed in cancerous tissues of BC patients in comparison with the non-cancerous tissues and the expressions were more prevalence in the MIBC groups. These findings corroborated the previously reported data (Pignot et al., 2013; Zhang et al., 2015) indicating a significant role of miRNA21 in bladder carcinogenesis.

The presence of a significant positive correlation between blood levels of Cd and Pb with the expression of miRNA21 in TCC and SCC groups suggests that there is a role of these metals in genetic alteration accompanied BC. These findings agree with other reports which suggest the involvement of miRNA21 in metal-induced carcinogenesis (Ling et al., 2012). Liu et al. reported expression of a number of miRNAs in Cd transformed human bronchial epithelial cells (Liu et al., 2015). These results come together to refer that miRNA21 has a role in metal induced carcinogenesis. No data are available in the literature about the relation between Cd and Pb exposure and expression of miRNAs among BC patients. However, Cd and Pb may alter miRNAs expression in other diseases. In an experimental study, Fay et al. reported that alteration in expression of 44 miRNAs may play a role in the pathophysiology of Cd nephrotoxicity (Fay et al., 2018). In another study, the exposure to Pb during early life affected the expression of miRNAs that related to Alzheimer disease (Masoud et al., 2016). Among occupationally exposed workers, miRNA21 was associated with Pb toxicity (Xu et al., 2017).

5. Conclusion

The present work proposed the positive correlation between blood concentrations Cd and Pb with the expression of miRNA21 in BC tissues. These finding provide additional information about the role of miRNA21 in metal induced bladder carcinogenesis. Descriptive and functional studies are strongly recommended to speak about the role of miR-21 in metal-induced bladder carcinogenesis.

Declarations

Author contribution statement

A. Awadalla: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

W. Mortada: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

H. Abol-Enein and A. Shokeir: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This work was supported by the Science & Technology development Fund (STDF), Ministry of Scientific Research, Egypt (5236).
Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

Abdeen, A., et al., 2019. Cadmium overload modulates piroxicam-regulated oxidative damage and apoptotic pathways. Environ. Sci. Pollut. Control Ser. 26, 25167–25177.
Al Bakheet, S.A., Attafi, I.M., Maayah, Z.H., Abd-Allah, A.R., Astri, Y.A., Kornshy, H.M., 2013. Effect of long-term human exposure to environmental heavy metals on the expression of detoxification and DNA repair genes. Environ. Pollut. 181, 226–232.
Ambros, V., 2004. The functions of animal microRNAs. Nature 431, 350–355.
Andjelkovic, M., et al., 2019. Toxic effect of acute cadmium and lead exposure in rat blood, liver, and kidney. Int. J. Environ. Res. Publ. Health 16, 274.
ATSDR, 2019. ATSDR chemicals_phc/en/. (Accessed 21 August 2020).
Bautista-Sánchez, D., et al., 2020. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol. Ther. Nucleic Acids, Buha, A., et al., 2018. Overview of cadmium thyroid disrupting effects and mechanisms. Int. J. Mol. Sci. 19, 1501.
CDC, 2013. Adult Blood Lead Epidemiology and Surveillance (ABLES). US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health. https://www.cdc.gov/niosh/topics/ables/description.html.
Chang, C.H., et al., 2016. Association between levels of urinary heavy metals and urinary heavy metal concentrations of some metal ions in the blood of patients with brain tumors and associated medical conditions in the US adult population. Int. J. Environ. Health Res. 22, 105–118.
Mortada, W., Kenawey, L., Abdel-Rhaman, M., El-Gamal, G., Moalla, S., 2017. A new thiourea derivative [2-(3-ethylthiourea) benzoic acid] for cloud point extraction of some trace metals in water, biological and food samples. J. Trace Elem. Med. Biol. 44, 266–273.
Flora, G., Gupta, D., Tiwari, A., 2012. Toxicity of lead: a review with recent updates. Interdiscipl. Toxicol. 5, 47–58.
Golabek, T., Darewicz, B., Borawska, M., Markiewicz, R., Socha, K., Kudelski, J., 2009. Toxic effect of acute cadmium and lead exposure in rat blood, liver, and kidney. Int. J. Environ. Res. Publ. Health 16, 274.
Lei, X., Liu, X., Wu, Y., Wu, Q., Wang, G., Yang, Z., Li, L., 2017. MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget 8, 32370.
Livali, K.J., Schmittinger, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2 ΔΔCT method. Methods 25,402–408.
Masoud, A.M., Bihaqi, S.W., Machan, J.T., Zawia, N.H., Rennehan, W.E., 2016. Early-life exposure to lead (Pb) alters the expression of microRNA that target proteins associated with Alzheimer’s disease. J. Alzheimer. Dis. 51, 1257–1264.
Mendy, A., Gasana, J., Vieira, E.R., 2012. Urinary heavy metals and associated medical conditions in the US adult population. Int. J. Environ. Health Res. 22, 105–118.
Moyer, T., 2015. Toxic metals. In: CA Burtis, D.B. (Ed.), Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, seventh ed. edn. Elsevier, Amsterdam, p. 598.
Volanis, D., Kadiyska, T., Galanis, A., Delakas, D., Logotheti, S., Zoumpourlis, V., 2010. Toxic metal quantification in bladder biopsies from tumoral lesions of Tunisian patients with bladder cancer and controls subjects. Environ. Sci. Pollut. Control Ser. 21, 11433–11438.
Feng, Y.-H., Tsoa, C.-J., 2016. Emerging role of microRNA-21 in cancer. Biomed. Res. 5, 395–402.
Cheng, C.H., et al., 2016. Association between levels of urinary heavy metals and increased risk of uterine abnormalities. Int. J. Urol. 23, 233–239.
Fay, M.J., et al., 2018. Cadmium nephrotoxicity is associated with altered microRNA expression in the rat renal cortex. Toxins 6, 16.
Feki-Tounsi, M., Hamza-Chaffai, A., 2014. Cadmium as a possible cause of bladder cancer: a review of accumulated evidence. Environ. Sci. Pollut. Control Ser. 21, 10561–10573.
Feki-Tounsi, M., Olmedo, P., Gil, F., Khif, R., Mhiri, M., N., Rebai, A., Hamza-Chaffai, A., 2013. Cadmium in blood of Tunisian men and risk of bladder cancer: interactions with arsenic exposure and smoking. Environ. Sci. Pollut. Control Ser. 20, 7204–7213.
Feki-Tounsi, M., Olmedo, P., Gil, F., Mhiri, M., Rebai, A., Hamza-Chaffai, A., 2014. Trace metal quantification in bladder biopsies from tumoral lesions of Tunisian cancer and controls subjects. Environ. Sci. Pollut. Control Ser. 21, 11433–11438.
Golabek, T., Darewicz, B., Borawska, M., Markiewicz, R., Socha, K., Kudelski, J., 2009. Lead concentration in the bladder tissue and blood of patients with bladder cancer. Scandinavian. J. Urol. Nephrol. 43, 467–470.
Hou, L., Wang, D., Baccarelli, A., 2011. Environmental chemicals and microRNAs. Mutat. Res. Fund. Mol. Mech. Mutagen 714, 105–112.
Huff, J., Lunn, R.M., Wadkile, M.P., Tomatis, L., Infante, P.F., 2007. Cadmium-induced cancers in animals and in humans. Int. J. Occup. Environ. Health. 15, 202–212.
Kadam, S., Joshi, A., 2020. MicroRNAs and their potential role in malignant transformation of human bronchial epithelial cells induced by cadmium. BioMed Res. Int. 2015.
Huang, J., Liu, X., Wu, Y., Wu, Q., Wang, G., Yang, Z., Li, L., 2017. MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget 8, 32370.
Hou, L., Wang, D., Baccarelli, A., 2011. Environmental chemicals and microRNAs. Mutat. Res. Fund. Mol. Mech. Mutagen 714, 105–112.
Huff, J., Lunn, R.M., Wadkile, M.P., Tomatis, L., Infante, P.F., 2007. Cadmium-induced cancers in animals and in humans. Int. J. Occup. Environ. Health 15, 202–212.
Huff, J., Lunn, R.M., Wadkile, M.P., Tomatis, L., Infante, P.F., 2007. Cadmium-induced cancers in animals and in humans. Int. J. Occup. Environ. Health. 15, 202–212.
Huff, J., Lunn, R.M., Wadkile, M.P., Tomatis, L., Infante, P.F., 2007. Cadmium-induced cancers in animals and in humans. Int. J. Occup. Environ. Health. 15, 202–212.
Kadam, S., Joshi, A., 2020. MicroRNAs and their potential role in malignant transformation of human bronchial epithelial cells induced by cadmium. BioMed Res. Int. 2015.
Kadam, S., Joshi, A., 2020. MicroRNAs and their potential role in malignant transformation of human bronchial epithelial cells induced by cadmium. BioMed Res. Int. 2015.